Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
The 3 Best Cheap Stocks to Buy in December
02:00pm, Sunday, 10'th Dec 2023
The rising market in 2023 has not lifted all boats. Some stocks look extremely cheap right now.
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
05:51am, Sunday, 10'th Dec 2023
AbbVie announced two major acquisitions in seven days. Buying ImmunoGen and Cerevel Therapeutics should make AbbVie more competitive in oncology and neuroscience.
How To Invest $100,000 Today In A Sleep Well Portfolio
09:00am, Saturday, 09'th Dec 2023
The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. If the volatility of the stock market keeps you awake at
Better Dividend Stock: AbbVie vs. Medical Properties Trust
05:12am, Saturday, 09'th Dec 2023
AbbVie offers an above-average dividend yield and its payout has risen sharply in recent years. Medical Properties Trust slashed its dividend in half this year and it still offers an enormous 12.6% yi
$19 Billion in a Week: AbbVie Makes Two Big Bets
07:00am, Friday, 08'th Dec 2023
The drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers.
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
05:38am, Friday, 08'th Dec 2023
On Dec. 6, AbbVie agreed to acquire Cerevel Therapeutics for $8.7 billion. On Nov. 30, AbbVie announced a $10.1 billion acquisition of ImmunoGen.
Healthcare Gems: 3 Essential Long-Term Stock Picks
06:00pm, Thursday, 07'th Dec 2023
Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world's most pressing issues from heart disease, Alzheim
AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio
05:40pm, Thursday, 07'th Dec 2023
Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
01:35pm, Thursday, 07'th Dec 2023
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
10:50am, Thursday, 07'th Dec 2023
CNBC's David Faber delivers his latest Faber Report.
AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B
10:24am, Thursday, 07'th Dec 2023
AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion. Cerevel's
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout
09:51am, Thursday, 07'th Dec 2023
U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
06:46am, Thursday, 07'th Dec 2023
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
Is AbbVie Stock a Buy Now?
06:05am, Thursday, 07'th Dec 2023
AbbVie's oncology business is getting bigger, as the company announced plans to acquire ImmunoGen. Through the $10.1 billion deal, the company will acquire a promising cancer therapy in Elahere.
AbbVie Does It Again With Fresh Pharma Acquisition
05:33am, Thursday, 07'th Dec 2023
AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share, or about $8.7 billion, in an all-cash deal.
